Starsource Multitrade Limited has notified the Bombay Stock Exchange of its decision to claim exemption from the Annual Secretarial Compliance Report requirement for the financial year ending March 31, 2026. The company, formerly known as Chemo Pharma Laboratories Limited, is utilizing the exemption provision under Regulation 15(2) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Exemption Criteria

The company qualifies for the exemption based on specific financial thresholds established by SEBI regulations. Under Regulation 15(2), companies with paid-up equity share capital not exceeding ₹10 crore and net worth not exceeding ₹25 crore are exempt from certain compliance requirements.

Compliance Status and Future Commitments

Due to this exemption, Starsource Multitrade Limited is not required to submit the Corporate Governance Report for the year ended March 31, 2026, under Regulation 24A of SEBI Listing Regulations. The company has noted that audited figures for the year ended March 31, 2026, are still awaited, preventing the exact determination of the current net worth.

The company has provided assurance regarding future compliance obligations. Management has undertaken that if and when these regulations become applicable to the company, it will comply with all requirements within six months from the date the provisions become applicable.

Company Background

Starsource Multitrade Limited, with CIN L46900MH1942PLC003556, operates from its registered office at 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan - 421301, India. The company maintains its corporate headquarters at 1016, North Plaza, Near D Mart, Motera, Ahmedabad - 380005, India. The communication to BSE was signed by Ruchit Mehta, Managing Director & Chief Executive Officer, bearing DIN 08810586.

Starsource Multitrade Limited has fulfilled its quarterly regulatory obligations by submitting a confirmation certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The company, formerly known as Chemo Pharma Laboratories Limited, filed the mandatory certificate with the Bombay Stock Exchange on April 06, 2026.

Regulatory Compliance Details

The submission pertains to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This regulation requires companies to confirm their compliance with dematerialisation processes and related requirements on a quarterly basis.

Certificate Issuance and Confirmation

The confirmation certificate was issued by M/s. Purva Sharegistry (India) Private Limited, which serves as the company's Registrar and Share Transfer Agent (RTA). Purva Sharegistry holds SEBI registration number INR000001112 as a Category 1 Registrar for IPO and Share Transfer services.

The RTA confirmed that securities received from depository participants for dematerialisation during the quarter ended March 2026 were properly processed and confirmed to the depositories. The certificate validates that all security certificates received for dematerialisation were appropriately handled, with proper verification, mutilation, and cancellation procedures followed by the depository participants.

Corporate Leadership

The submission was signed by Ruchit Mehta, who serves as Managing Director and Chief Executive Officer of star source multi trade . Mehta holds Director Identification Number (DIN) 08810586 and executed the filing on behalf of the company.

Compliance Confirmation

Purva Sharegistry's compliance officer, Ms. Deepali Gaonkar, certified that the company maintained proper records and followed prescribed timelines for all dematerialisation processes. The confirmation ensures that the names of depositories were appropriately substituted in the register of members as registered owners within the required timeframes.

This quarterly submission represents part of the ongoing regulatory compliance framework that listed companies must maintain to ensure transparency and proper handling of securities in the dematerialised form.